

Response
Serial No. 08/851,965
Page 2

Claims 8, 30 and 31

Claims 8, 30 and 31, reprinted below for the convenience of the Examiner (with emphases added), are directed to methods for the treatment of gastritis and gastric ulceration:

91 8. ~~(b)(1)~~ A method for treating gastritis in a subject, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.

9 31. ~~(b)(1)~~ A method for treating gastric ulceration in a subject, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.

92 8. The method of claim 1, 2, 25, 26, 27, 28, 30, or 31, wherein said amylin agonist is ^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 1].

Kolterman et al.

Claims 8, 30, and 31 have been rejected under 35 U.S.C. §102(b)/§103(a) as allegedly anticipated by, or obvious over, Kolterman et al. (PCT Publication No. WO 95/07098), on the assertion that Kolterman et al. "would necessarily anticipate the presently claimed invention drawn to **the prevention** of gastritis/ulcers" (emphasis by the Examiner) because the method of Kolterman et al. "serves to inherently '**prevent**' or alternatively would be expected to **prevent** gastritis (or ulceration) . . ." (emphasis by Applicants).

Referring to the language of claims 8, 30 and 31, the rejection is respectfully traversed. Claims 30 and 31 recite methods for "treating" gastritis and gastric ulceration. They do not refer to methods of "preventing" gastritis and gastric ulceration. Claim 8 is dependent on method of treatment claims 30 or 31. Accordingly, notwithstanding the correctness of the Examiner's assertion, which is disputed, reconsideration and withdrawal of this rejection is respectfully requested.

Response
Serial No. 08/851,965
Page 3

Guidobono et al.

Claims 30 and 31 have also been rejected under 35 U.S.C. §102(b) as allegedly anticipated by Guidobono et al. (*Peptides*, Vol. 15(4), pp. 699-702, 1994). Again, the Examiner asserts that this rejection is based on assertion that the document teaches the prevention of gastritis and gastric ulcerations. Notwithstanding the correctness of this assertion, which is also disputed, as noted above claims 30 and 31 are specifically focused on methods of treating gastritis or gastric ulceration. Thus, withdrawal of this rejection is respectfully requested.

In conclusion, Applicants respectfully submit that all pending claims are in condition for allowance. The Examiner is invited to contact Applicants' undersigned Representative if it is believed that prosecution may be furthered thereby.

Respectfully Submitted,

Young et al.

Dated: 10-31-02

By: Lisa M. McGeehan

Lisa M. McGeehan
Reg. No. 41,185

Brobeck, Phleger & Harrison LLP
12390 El Camino Real
San Diego, CA 92130-2081
Direct Dial: (858)720-2584
Facsimile: (858)720-2555